◼ Archived
Business
🔮 fades ✓
Ophthalmology venture grabs investors’ attention, raises $330 million
Ollin Biosciences secures $330 million to challenge Roche's Vabsymo in retina disease treatment
Series B Financing
1 trends tracked about this subject — the full history, oldest to newest below.